Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Amphista Therapeutics Appoints Dr Martin Pass as CDO
Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]
Amphista Therapeutics Appoints CBO, Beverley Carr
Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the […]
Amphista Therapeutics Expands Research Team by Appointing Martin O'Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
Amphista Therapeutics, a Targeted Protein Degradation (TPD) biopharmaceutical company creating first-in-class cancer therapeutics that harness […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more